Nan Su

Nan Su


Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 October 2016 in Oncology Letters
Verified
Journal Article
Open access
PDF file
NSNan Su
Nan Su
PWPingping Wang
Pingping Wang
YLYan Li
Yan Li
β-catenin is the downstream effector of the Wnt signaling pathway, which regulates cell proliferation and differentiation. Activation of the Wnt/β‑catenin signaling pathway has been shown to positively correlate with prognosis in several types of malignancies. The present study aimed to determine the role of β‑catenin in multiple myeloma (MM) cells using lentiviruses expressing small interfering RNA (siRNA). The expression of β‑catenin in the MM cell line RPMI‑8826 was evaluated following β‑catenin knockdown by the siRNA. Subsequently, the activation of autophagy in MM cells was assessed by transmission electron microscopy and western blot analyses. Cell apoptosis and the expression of apoptosis‑related proteins following β‑catenin silencing was investigated by flow cytometry and western blotting, respectively. A significant decrease in β‑catenin expression was observed in the MM cell line expressing β‑catenin‑specific siRNA. Activation of autophagy was induced by β‑catenin silencing, as evidenced by increases in the number of autophagic vacuoles and the expression of the autophagy‑related proteins microtubule‑associated protein 1 light chain 3 and Beclin‑1. Furthermore, the expression of 5'‑adenosine monophosphate‑activated protein kinase was increased, and that of mechanistic target of rapamycin was decreased, following β‑catenin silencing. In addition, there was an increase in the rate of apoptosis of MM cells following β‑catenin silencing, accompanied by increased protein expression of phosphorylated p53, active caspase‑3 and B‑cell lymphoma (Bcl)‑2‑associated X protein, and decreased protein expression of Bcl‑2. The results of the present study suggested that β‑catenin silencing induced autophagy and apoptosis in MM cells. To the best of our knowledge, this is the first study to demonstrate that a β‑catenin deficiency induces autophagy in MM cells. These findings suggested that inhibition of β‑catenin could be a potential therapeutic target for patients with MM.

8 December 2023 in Frontiers in Immunology
Verified
Journal Article
Open access
JZJinjing Zhang
Jinjing Zhang
DCDali Cai
Dali Cai
RGRan Gao
Ran Gao
YMYuan Miao
Yuan Miao
YCYan Cui
Yan Cui
NSNan Su
Nan Su
Background: Follicular lymphoma (FL), a common indolent B-cell lymphoma, has the potential to transform into an aggressive lymphoma, such as diffuse large B-cell lymphoma (DLBCL). The outcome of patients with transformed follicular lymphoma (tFL) is poor, especially in patients with transformed lymphoma after chemotherapy and patients with progression within 24 months (POD24). Chimeric antigen receptor (CAR) T-cell therapy combined with autologous stem cell transplantation (ASCT) has promising antitumor efficacy.Case presentation: Here, we described a 39-year-old male patient who was initially diagnosed with FL that transformed into DLBCL with POD24, CD20 negativity, TP53 mutation, and a bulky mass after 3 lines of therapy, all of which were adverse prognostic factors. We applied a combination approach: CD19 CAR T-cell infusion following ASCT. Ibrutinib was administered continuously to enhance efficacy, DHAP was administered as a salvage chemotherapy, and ICE was administered as a bridging regimen. The patient underwent BEAM conditioning on days -7~ -1, a total of 3.8 × 106/kg CD34+ stem cells were infused on days 01~02, and a total of 108 CAR T cells (relmacabtagene autoleucel, relma-cel, JWCAR029) were infused on day 03. The patient experienced grade 2 cytokine release syndrome (CRS), manifesting as fever and hypotension according to institutional standards. There was no immune effector cell-associated neurotoxicity syndrome (ICANS) after CAR T-cell infusion. Finally, the patient achieved CMR at +1 month, which has been maintained without any other adverse effects.Conclusion: This case highlights the amazing efficacy of CD19 CAR T-cell therapy following ASCT for R/R tFL, thus providing new insight on therapeutic strategies for the future.

28 May 2024 in Frontiers in Oncology
Verified
Journal Article
Open access
PDF file
ZLZhenghua Liu
Zhenghua Liu
DCDali Cai
Dali Cai
NSNan Su
Nan Su
Background: Mycobacterium tuberculosis (MTB) is a relatively infrequent infection encountered during hematopoietic stem-cell transplantation (HSCT). The identification of MTB following HSCT remains a complex task, with delayed detection and misdiagnosis potentially resulting in unfavorable outcomes. Metagenomic next-generation sequencing (mNGS) represents a novel, highly sensitive, and rapid diagnostic tool in clinical settings for discerning intricate infections and detecting exceedingly rare pathogensMethods: With the aid of mNGS, we diagnosed MTB in the lymph nodes and lungs of two patients with hematological diseases following allogeneic peripheral blood hematopoietic stem cell transplantation. Both patients presented with a fever, localized symptoms, and clinical signs. Following inconclusive results from routine tests, impractical biopsy procedures, and unsuccessful responses to empirical treatments, mNGS was employed as a final recourse, revealing DNA fragments of MTB in blood samples.Results: The diagnoses were ultimately confirmed in conjunction with additional clinical evidence. The application of mNGS in MTB cases after allogeneic HSCT has rarely been reported. The mNGS technique can provide a prompt and highly sensitive indication leading to the definitive diagnosis of MTB in complex post-transplant scenarios.

21 July 2026 in Frontiers in Immunology
Verified
Journal Article
Open access
PDF file
SYShuai Yao
Shuai Yao
RZRan Zhang
Ran Zhang
WMWenbin Mo
Wenbin Mo
ZLZhenghua Liu
Zhenghua Liu
HZHeyang Zhang
Heyang Zhang
NSNan Su
Nan Su
Hematopoietic stem cell transplantation (HSCT) and chimeric antigen receptor T-cell (CAR-T) therapy are two major therapeutic approaches for hematologic malignancies. HSCT can provide durable disease control through conditioning-induced tumor cytoreduction, immune reconstitution, and graft-versus-leukemia effects, whereas CAR-T therapy provides antigen-specific antitumor activity and has reshaped the treatment landscape for relapsed or refractory leukemia, lymphoma, and multiple myeloma (MM). Despite these advances, both therapeutic approaches continue to face multiple challenges. HSCT is limited by disease relapse and transplant-related complications, while CAR-T therapy is challenged by antigen escape, limited persistence, and treatment-related toxicities. Increasing clinical experience suggests that HSCT and CAR-T therapy should not be viewed as competing strategies, but rather as complementary therapeutic approaches whose value depends on disease characteristics, depth of response, immune recovery, and transplant feasibility. On the one hand, CAR-T therapy can reduce tumor burden before transplantation, be incorporated into modified conditioning regimens, or be used after allogeneic HSCT (allo-HSCT) as prophylactic, preemptive, or salvage cellular therapy. On the other hand, HSCT can consolidate CAR-T-induced remission, provide hematopoietic support in selected settings, and create a post-transplant immune environment that may facilitate subsequent CAR-T-cell therapy. In this review, we summarize the current evidence for HSCT–CAR-T integration in leukemia, lymphoma, and MM. We discuss major integration strategies, including HSCT after CAR-T therapy, CAR-T-assisted conditioning, autologous stem cell transplantation (ASCT)–CAR-T sequential strategies, and CAR-T therapy after allo-HSCT. We aim to help match appropriate patients to the most suitable HSCT–CAR-T strategies and thereby improve clinical decision-making.